Beyond Air, Inc. (NASDAQ:XAIR - Get Free Report) CEO Steven A. Lisi acquired 1,476,626 shares of the company's stock in a transaction dated Thursday, September 26th. The shares were acquired at an average price of $0.50 per share, for a total transaction of $738,313.00. Following the completion of the purchase, the chief executive officer now owns 3,249,411 shares of the company's stock, valued at approximately $1,624,705.50. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

NASDAQ:XAIR opened at $0.30 on Wednesday. Beyond Air, Inc. has a 52 week low of $0.30 and a 52 week high of $2.61. The firm has a 50 day moving average of $0.44 and a 200 day moving average of $0.91. The company has a quick ratio of 2.42, a current ratio of 2.63 and a debt-to-equity ratio of 0.84. The stock has a market capitalization of $13.86 million, a price-to-earnings ratio of -0.17 and a beta of -0.11.

Beyond Air (NASDAQ:XAIR - Get Free Report) last posted its earnings results on Tuesday, August 6th. The company reported ($0.27) EPS for the quarter, beating analysts' consensus estimates of ($0.39) by $0.12. Beyond Air had a negative net margin of 3,272.46% and a negative return on equity of 240.15%Varanasi Investment. The company had revenue of $0.68 million during the quarter, compared to analysts' expectations of $0.72 million. During the same quarter in the prior year, the company posted ($0.45) earnings per share. As a group, sell-side analysts anticipate that Beyond Air, Inc. will post -1.03 earnings per share for the current fiscal year.Hyderabad Stocks

Institutional investors and hedge funds have recently made changes to their positions in the stock. Vanguard Group IncAhmedabad Wealth Management. lifted its stake in shares of Beyond Air by 5.0% during the first quarter. Vanguard Group Inc. now owns 1,399,298 shares of the company's stock worth $2,435,000 after buying an additional 66,224 shares during the period. Gendell Jeffrey L lifted its stake in shares of Beyond Air by 2.8% during the fourth quarter. Gendell Jeffrey L now owns 1,120,297 shares of the company's stock worth $2,196,000 after buying an additional 30,000 shares during the period. Finally, Point72 Asia Singapore Pte. Ltd. acquired a new stake in shares of Beyond Air during the second quarter worth $47,000. 31.50% of the stock is currently owned by institutional investors and hedge funds.

A number of research firms have recently issued reports on XAIR. Piper Sandler dropped their price objective on shares of Beyond Air from $3.50 to $1.00 and set an "overweight" rating on the stock in a research note on Wednesday, August 7th. Roth Capital upgraded shares of Beyond Air to a "strong-buy" rating in a research note on Friday, August 16th. BTIG Research downgraded shares of Beyond Air from a "buy" rating to a "neutral" rating in a research note on Tuesday, June 25th. Finally, Roth Mkm reiterated a "buy" rating and set a $2.00 price objective on shares of Beyond Air in a research note on Friday, August 16th. One equities research analyst has rated the stock with a hold rating, three have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of "Buy" and a consensus price target of $3.67.

View Our Latest Research Report on Beyond Air (Get Free Report)

Beyond Air, Inc operates as a commercial-stage medical device and biopharmaceutical company in the United States. The company engages in the development of LungFit platform, a nitric oxide generator and delivery system. It offers LungFit PH for the treatment of persistent pulmonary hypertension of the newborn.Five stocks we like better than Beyond AirThe 3 Best Retail Stocks to Shop for in AugustWhy Lennar Stock Could Be the Best Play in the Housing MarketIndustrial Products Stocks Investing 2 Energy Stocks Fueling the AI Datacenter Boom REIT Stocks - Best REIT Stocks to Add to Your Portfolio TodayWill Marinus Pharmaceuticals Be the Next Big Winner in Biotech?